A randomized phase 2 study of ARQ 197 [ArQule] versus gemcitabine in treatment-naive patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma.

Trial Profile

A randomized phase 2 study of ARQ 197 [ArQule] versus gemcitabine in treatment-naive patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs Gemcitabine; Tivantinib
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2012 Actual patient number changed from 72 to 43 as reported by ClinicalTrials.gov.
    • 01 May 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top